News

Filter

Current filters:

RegeneronNovartis

Asia-Pacific region macular degeneration market to see modest growth; report

Asia-Pacific region macular degeneration market to see modest growth; report

30-10-2013

Due to the absence of promising products in the pipeline or expected new drug launches, the macular degeneration…

Asia-PacificBayerEyleaLucentisMacugenMarkets & MarketingNovartisOphthalmicsPfizerPharmaceuticalRegeneronRoche

EU approval for Ilaris in active systemic juvenile idiopathic arthritis

03-09-2013

Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegeneronRegulation

Novartis gets EU approval for expanded use of Ilaris, acute gouty arthritis

05-03-2013

The European Commission (EC) has approved Swiss drug major Novartis' (NOVN: VX) llaris (canakinumab,…

Anti-Arthritics/RheumaticsEuropeIlarisNovartisPharmaceuticalRegeneronRegulation

Ph III studies show Bayer and Regeneron VEGF Trap-Eye in wet AMD meets primary endpoints versus Lucentis

22-11-2010

German drug major Bayer (BAY: DE) and US partner Regeneron Pharmaceuticals (Nasdaq: REGN) reveal that,…

afliberceptBayerLucentisNovartisOpthalmicsPharmaceuticalRegeneronResearchRocheVEGF Trap-Eye

Back to top